SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
CEPH
An SI Board Since June 1996
Posts SubjectMarks Bans Symbol
998 24 0 CEPH
Emcee:  Stephanie Mocilan Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
73 The Standard and Poor (SP) report of March 15, 1997 indicates that the stock beharkenman-3/17/1997
72 Obviously, your knowledge of Cephalon is limited to what is said in the SEC staKurtVedder-3/17/1997
71 Fact #4: Besides Myotrophin/Provigil all other CEPH products are at least 3 toharkenman-3/15/1997
70 FACT #3: Myotrophin composition rhIGF-I is in the public domain and therefore charkenman-3/15/1997
69 FACT 2: "With respect to PROVIGIL (modafinil), there are presently severalharkenman-3/15/1997
68 Fact 1: ALS affects approximately 20,000 people in the United States. The Compaharkenman-3/15/1997
67 You're getting off the point now. Originally, I responded to your posts beKurtVedder-3/14/1997
66 First Call predicts consensus earnings of $-2.82 for 1997 with 8 : 1 brokers reharkenman-3/14/1997
65 What about the 1 in 100,000 ALS population incidence? An orphan drug is just thharkenman-3/13/1997
64 The reasons you give for shorting Cephalon are not convincing. First you stateKurtVedder-3/13/1997
63 The information I posted was taken from the SEC pages. Tell CEPH or the SEC thharkenman-3/12/1997
62 The information that you have been posting regarding Cephalon is both disillusiKurtVedder-3/12/1997
61 This negative information was published by CEPH upon their latest stock offerinharkenman-3/7/1997
60 i agree with you. short cephalon. the companys drug for ALS sucks. their datThe Dermatologist-3/3/1997
59 Those two are the only ones withing CEPH with brains. Its a job you know whichharkenman-3/1/1997
58 Even though you say Michael Murray, VP and Monroe Klein, VP sold 100% of their bysfbay-3/1/1997
57 Update CEPH Closed today $23 3/4 down 1 3/8 feb 24 Insider trading repharkenman-2/24/1997
56 Short interest for Cephalon went up 17.4 % in January 1997 from 1.33 million toharkenman-2/22/1997
55 If this the only information out there on this company, Taken from the Edgar daharkenman-2/16/1997
54 If this the only information out there on this company, Taken from the Edgar daharkenman-2/16/1997
53 This analysis was done by a friend of mine not taking into considersation any fharkenman-2/15/1997
52 Cephalon filed for NDA on Feb 11 right on schedule. FDA is expected to come to bysfbay-2/14/1997
51 It looks like FDA approval is right around the corner. Lots of buying today. TDan Booras-2/5/1997
50 Victor, NeuroInvestment has had a $50 target on CEPH since at least 7/96. The Mark Nelson-1/25/1997
49 NeuroInvestment currently has a $50 target. businesswire.comvictor gupta-1/17/1997
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News